Management of patients with inflammatory bowel disease and spondyloarthritis - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Expert Review of Clinical Pharmacology Année : 2017

Management of patients with inflammatory bowel disease and spondyloarthritis

Résumé

Introduction: More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA. Areas covered: We give an overview of the classification, the epidemiology and the diagnosis of IBD and SpA. The treatment goals, the pharmacologic management options and the available treatment guidelines in IBD patients with SpA are discussed. Expert commentary: The coexistence of IBD and SpA generates challenges and opportunities for both the gastroenterologist and the rheumatologist. The potential of drugs with a gut-specific mode of action in the treatment of IBD-related arthritis warrants further exploration
Fichier principal
Vignette du fichier
pouillon.pdf (1.26 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01715137 , version 1 (22-02-2018)

Identifiants

Citer

Lieven Pouillon, Peter Bossuyt, Joke Vanderstukken, David Moulin, Patrick Netter, et al.. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Review of Clinical Pharmacology, 2017, 10 (12), pp.1363-1374. ⟨10.1080/17512433.2017.1377609⟩. ⟨hal-01715137⟩
172 Consultations
1695 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More